[go: up one dir, main page]

MX2015014688A - Tiazoles y usos de los mismos. - Google Patents

Tiazoles y usos de los mismos.

Info

Publication number
MX2015014688A
MX2015014688A MX2015014688A MX2015014688A MX2015014688A MX 2015014688 A MX2015014688 A MX 2015014688A MX 2015014688 A MX2015014688 A MX 2015014688A MX 2015014688 A MX2015014688 A MX 2015014688A MX 2015014688 A MX2015014688 A MX 2015014688A
Authority
MX
Mexico
Prior art keywords
salts
compounds
compositions
methods
thiazoles
Prior art date
Application number
MX2015014688A
Other languages
English (en)
Inventor
Tatyana Dekhtyar
M-Akhteruzzaman Molla
Anil Vasudevan
Artour Gomtsian
Tami J Pilot-Matias
Teresa Lok-Chan Ng
Katerina Sarris
Ana Aguirre
Mikhail Chafeev
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015014688A publication Critical patent/MX2015014688A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta descripción se refiere a: (a) compuestos y sales de los mismos que, entre otras cosas, inhibe la infección por RSV y/o replicación; (b) intermedios útiles para la preparación de tales compuestos y sales; (c) composiciones que comprenden tales compuestos y sales; (d) métodos para preparar tales intermedios, compuestos, sales, y composiciones; (e) métodos de uso de tales compuestos, sales, y composiciones; y (f) kits que comprenden tales compuestos, sales y composiciones.
MX2015014688A 2013-04-22 2014-04-22 Tiazoles y usos de los mismos. MX2015014688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361814523P 2013-04-22 2013-04-22
PCT/US2014/035014 WO2014176268A1 (en) 2013-04-22 2014-04-22 Thiazoles and uses thereof

Publications (1)

Publication Number Publication Date
MX2015014688A true MX2015014688A (es) 2016-02-19

Family

ID=51792340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014688A MX2015014688A (es) 2013-04-22 2014-04-22 Tiazoles y usos de los mismos.

Country Status (9)

Country Link
US (1) US10233179B2 (es)
EP (1) EP2988742A4 (es)
JP (1) JP6434496B2 (es)
CN (1) CN105307651A (es)
AU (1) AU2014257164B2 (es)
BR (1) BR112015026847A2 (es)
CA (1) CA2909938A1 (es)
MX (1) MX2015014688A (es)
WO (1) WO2014176268A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8271106B2 (en) 2009-04-17 2012-09-18 Hospira, Inc. System and method for configuring a rule set for medical event management and responses
AU2012325937B2 (en) 2011-10-21 2018-03-01 Icu Medical, Inc. Medical device update system
ES2908320T3 (es) 2013-03-06 2022-04-28 Icu Medical Inc Método de comunicación de dispositivos médicos
AU2014312122A1 (en) 2013-08-30 2016-04-07 Icu Medical, Inc. System and method of monitoring and managing a remote infusion regimen
US9662436B2 (en) 2013-09-20 2017-05-30 Icu Medical, Inc. Fail-safe drug infusion therapy system
CA2945647C (en) 2014-04-30 2023-08-08 Hospira, Inc. Patient care system with conditional alarm forwarding
US9724470B2 (en) 2014-06-16 2017-08-08 Icu Medical, Inc. System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy
US9539383B2 (en) 2014-09-15 2017-01-10 Hospira, Inc. System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein
CN105647151A (zh) * 2016-04-15 2016-06-08 无锡智谷锐拓技术服务有限公司 一种防霉塑料
CN105670266A (zh) * 2016-04-15 2016-06-15 无锡智谷锐拓技术服务有限公司 一种防霉塑料的制备方法
CN105838176A (zh) * 2016-06-02 2016-08-10 扬州兰都塑料科技有限公司 一种电缆防污水性涂料
CN105838177A (zh) * 2016-06-02 2016-08-10 扬州兰都塑料科技有限公司 一种电缆防污剂
CN106010023A (zh) * 2016-06-02 2016-10-12 扬州兰都塑料科技有限公司 一种电缆防污水性涂料的制备方法
EP4297379A3 (en) 2018-07-17 2024-01-10 ICU Medical, Inc. Systems and methods for facilitating clinical messaging in a network environment
EP3824386B1 (en) 2018-07-17 2024-02-21 ICU Medical, Inc. Updating infusion pump drug libraries and operational software in a networked environment
AU2020267477B2 (en) 2019-05-08 2025-09-18 Icu Medical, Inc. Threshold signature based medical device management
US11590057B2 (en) 2020-04-03 2023-02-28 Icu Medical, Inc. Systems, methods, and components for transferring medical fluids
EP4208798A4 (en) 2020-09-05 2024-10-09 ICU Medical, Inc. IDENTITY-BASED SECURE COMMUNICATION OF MEDICAL DEVICES

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
WO2002049993A2 (en) * 2000-09-29 2002-06-27 Neurogen Corporation High affinity small molecule c5a receptor modulators
US6723743B1 (en) * 1999-09-28 2004-04-20 Neurogen Corporation High affinity small molecule C5a receptor modulators
AU779426B2 (en) * 1999-11-15 2005-01-27 Janssen Pharmaceutica N.V. Triazoles as farnesyl transferase inhibitors
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
GB0119172D0 (en) * 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
KR100492252B1 (ko) * 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
EP1565452B1 (en) 2002-11-08 2012-04-04 Novartis International Pharmaceutical Ltd. 3-substituted-6-aryl pyridines as ligands of c5a receptors
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
DE102004024773A1 (de) 2004-05-17 2005-12-15 Grünenthal GmbH Substituierte 2,5-Diaminomethyl-1H-pyrrole
US7632833B2 (en) 2004-07-01 2009-12-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007058322A1 (ja) * 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007067511A2 (en) 2005-12-06 2007-06-14 Merck & Co., Inc. Morpholine carboxamide prokineticin receptor antagonists
US8618122B2 (en) * 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
CA2714008A1 (en) 2008-01-29 2009-08-06 Janssen Pharmaceutica N.V. 2-amino quinoline derivatives useful as inhibitors of .beta.-secretase (bace)
WO2010003624A2 (en) * 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AU2009314200B2 (en) 2008-11-17 2011-11-17 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
CN102272100B (zh) * 2008-12-05 2016-08-17 分子制药洞察公司 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法
US8211402B2 (en) * 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
JPWO2010147094A1 (ja) 2009-06-16 2012-12-06 小野薬品工業株式会社 スピロ結合した環状基を有する化合物およびその用途
MX2012007429A (es) * 2009-12-23 2012-07-23 Plexxikon Inc Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma.
EP2560969B1 (en) * 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
JP2011219476A (ja) * 2011-04-19 2011-11-04 Neurogen Corp 高親和性低分子Ｃ５ａ受容体調節物質
WO2012150952A1 (en) 2011-05-04 2012-11-08 Forma Tm, Llc Novel compounds and compositions for the inhibition of nampt

Also Published As

Publication number Publication date
EP2988742A4 (en) 2016-10-19
AU2014257164A1 (en) 2015-11-05
BR112015026847A2 (pt) 2017-07-25
US10233179B2 (en) 2019-03-19
CN105307651A (zh) 2016-02-03
AU2014257164B2 (en) 2018-10-11
WO2014176268A1 (en) 2014-10-30
JP2016517868A (ja) 2016-06-20
CA2909938A1 (en) 2014-10-30
US20160068521A1 (en) 2016-03-10
EP2988742A1 (en) 2016-03-02
JP6434496B2 (ja) 2018-12-05

Similar Documents

Publication Publication Date Title
MX2015014688A (es) Tiazoles y usos de los mismos.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX381417B (es) Inhibidores de glucosidasa.
MX2017007629A (es) Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX377786B (es) Procedimiento para la preparacion de cetonas fenoxifenilicas sustituidas.
JOP20170100B1 (ar) توليف مركبات إندازول
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
MX2015017156A (es) Inhibidores de bace.
AU2015261096A8 (en) Process for preparing phosphorus-containing cyanohydrins
NZ711192A (en) Process for making benzoxazepin compounds
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
IN2014MN01671A (es)
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂
MX385672B (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida.
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
MX2014009933A (es) Diaminopirimidinas utiles como inhibidores del virus sincitial respiratorio humano (rsv).
IN2013DE02503A (es)
MX379825B (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfuron.
PH12017500492A1 (en) Crystalline bace inhibitors
PH12015502703A1 (en) Pharmaceutical compositions